Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Cited by (1,021)

Items 501–600 of 1,021

1. The Impact of Genomic Changes on Treatment of Lung Cancer
   Stephanie Cardarella, Bruce Evan Johnson · 2013 · American Journal of Respiratory and Critical Care Medicine
2. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer
   Pietrantonio, Filippo, Oddo, Daniele, Gloghini, Annunziata, Valtorta, Emanuele, Berenato, Rosa, Barault, Ludovic, Caporale, Marta, Busico, Adele, Morano, Federica, Gualeni, Ambra Vittoria et al. · 2016 · Cancer Discovery
3. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
   Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki et al. · 2019 · Cancer Research
4. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics
   Jing Zhang, Zhimin Hu, Calista A. Horta, Jing Yang · 2022 · Seminars in Cancer Biology
5. Targeted Therapies for Lung Cancer
   Jill E. Larsen, Tina Cascone, David E. Gerber, John Victor Heymach, John Dorrance Minna · 2011 · The Cancer Journal
6. E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis
   Min Lu, Scot A. Marsters, Xiaofen Ye, Elizabeth Luis, Lino C. Gonzalez, Avi Ashkenazi · 2014 · Molecular Cell
7. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer
   Chul Kim, Chuong D. Hoang, Aparna Hemant Kesarwala, David S. Schrump, Udayan Guha, Arun Rajan · 2016 · Journal of Thoracic Oncology
8. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
   Jinnan Yue, Dacheng Lv, Caiyun Wang, Ling Li, Qingnan Zhao, Hongzhuan Chen, Lu Xu · 2018 · Oncogene
9. An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
   Kimio Yonesaka, Naoki Takegawa, Satomi Watanabe, Koji Haratani, Hisato Kawakami, Kazuko Sakai, Yasutaka Chiba, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani et al. · 2018 · Oncogene
10. The next tier of EGFR resistance mutations in lung cancer
    Hannah Lea Tumbrink, Alena Heimsoeth, Martin L. Sos · 2020 · Oncogene
11. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
    Mariacarmela Santarpía, Alessia Liguori, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla, Rafael Rosell · 2017 · Lung Cancer Targets and Therapy
12. Epithelial-mesenchymal transition
    Cecilia Xi Zhang, Ruby Yun‐Ju Huang, Guojun Sheng, Jean Paul Thiery · 2025 · Cell
13. Epidermal growth factor receptor in non-small cell lung cancer.
    C. Prabhakar · 2015 · PubMed Central
14. EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Erjing Ke, Yi-Long Lung Cancer Wu · 2016 · Trends in Pharmacological Sciences
15. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer
    Francesco Facchinetti, Ludovic Lacroix, Laura Mezquita, Jean‐Yves Scoazec, Yohann Loriot, Lambros Tselikas, Anas Gazzah, Étienne Rouleau, Julien Adam, Stefan Michiels et al. · 2020 · European Journal of Cancer
16. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    Antonio Jimeno, Keisuke Shirai, Minsig Choi, Janessa J. Laskin, Mark D. Kochenderfer, Alexander I. Spira, Vivian Jean M. Cline-Burkhardt, Eric Winquist, Diana Felice Hausman, Luke N. Walker et al. · 2014 · Annals of Oncology
17. Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
    Helena Alexandra Yu, Gregory J. Riely · 2013 · Journal of the National Comprehensive Cancer Network
18. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
    Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Mónica Garzón‐Ibáñez, Ariadna Balada‐Bel, Jordi Bertrán-Alamillo, Santiago Viteri, Noemı́ Reguart, M. A. Muñoz-Quintana, Pilar Lianes Barragán, Carlos Camps et al. · 2017 · Annals of Oncology
19. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
    Geeta G. Sharma, Inês Andrade Mota, Luca Mologni, Enrico Patrucco, Carlo B Gambacorti-Passerini, Roberto Chiarle · 2018 · Cancers
20. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Maximilian Johannes Hochmair, Alessandro Morabito, Desirée Hao, Cheng‐Ta Yang, Ross Andrew Soo, James Chih‐Hsin Yang, Rasim A. Gucalp, Balázs Halmos, Lara Wang, Amanda Golembesky et al. · 2018 · Future Oncology
21. Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR -Mutant Lung Cancers
    Michael David Offin, Romel Somwar, Natasha Rekhtman, Ryma Benayed, Jason C. Chang, Andrew J. Plodkowski, Allan J.W. Lui, Juliana Eng, Marc K. Rosenblum, Bob T. Li et al. · 2018 · JCO Precision Oncology
22. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
    Martin Schüler, Rossana Berardi, Wan‐Teck Lim, Maja J.A. de Jonge, Todd Michael Bauer, Analía Azaro, Maya Gottfried, Ji‐Youn Han, D. H. Lee, M. Wollner et al. · 2020 · Annals of Oncology
23. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
    Leilei Wu, Linping Ke, Zhenshan Zhang, Jinming Yu, Xue Meng · 2020 · Frontiers in Oncology
24. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
    Christine Marie Lovly, William J. Pao · 2012 · Science Translational Medicine
25. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Takeshi Yoshida, Lanxi Song, Yun Bai, Fumi Kinose, Jiannong Li, Kim C. Ohaegbulam, Teresita Muñoz-Antonia, Xiaotao Qu, Steven A. Eschrich, Hidetaka Uramoto et al. · 2016 · PLoS ONE
26. Molecular Signatures of the Insulin-Like Growth Factor 1-Mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers
    Armando Cevenini, Stefania Orrù, Annamaria Mancini, Andreina Alfieri, Pasqualina Buono, Esther Imperlini · 2018 · International Journal of Molecular Sciences
27. Acquired resistance mechanisms to osimertinib: The constant battle
    Ziad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, Samir Hachem, Roland Eid, Hampig Raphaël Kourié, David Planchard · 2023 · Cancer Treatment Reviews
28. Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
    Lelais, Gérald, Epple, Robert, Marsilje, Thomas H., Long, Yun O., McNeill, Matthew, Chen, Bei, Lu, Wenshuo, Anumolu, Jaganmohan, Badiger, Sangamesh, Bursulaya, Badry et al. · 2016 · Journal of Medicinal Chemistry
29. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
    Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E. et al. · 2018 · Clinical Cancer Research
30. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
    Wěi Li, Shengxiang Ren, Jiayu Li, Aiwu Li, Lihong Fan, Xuefei Li, Cao Zhao, Yayi He, Guanghui Gao, Xiaoxia Chen et al. · 2014 · Lung Cancer
31. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
    Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eléonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse et al. · 2017 · Clinical Lung Cancer
32. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
    E‐E Ke, Qing Hua Zhou, Qiu-Yi Zhang, Jian Su, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Hai‐Yan Tu, Hong‐Hong Yan et al. · 2017 · Journal of Thoracic Oncology
33. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
    Giuseppe Giaccone, Yongfeng He · 2023 · Seminars in Cancer Biology
34. Cellular and molecular biology of small cell lung cancer: an overview.
    Niki Karachaliou, Sara Pilotto, Chiara Lazzari, Emilio Bria, Filippo de Marinis, Rafael Rosell · 2016 · Europe PMC (PubMed Central)
35. Emerging evidence of epithelial‐to‐mesenchymal transition in lung carcinogenesis
    Mitsuo Sato, David S. Shames, Yoshinori Hasegawa · 2012 · Respirology
36. EGFR mutations in lung cancer: from tissue testing to liquid biopsy
    Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, Alessia Iannaccone, Nicoletta Chicchinelli, Renato Franco, Antônio Rossi et al. · 2015 · Future Oncology
37. Surgery for NSCLC in the era of personalized medicine
    Tetsuya Mitsudomi, Kenichi Suda, Yasushi Yatabe · 2013 · Nature Reviews Clinical Oncology
38. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond
    Mizuki Nishino · 2018 · American Society of Clinical Oncology Educational Book
39. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
    Maria Lie Lotsberg, Katarzyna Wnuk-Lipińska, Stéphane Terry, Tuan Zea Tan, Ning Lü, Laura Trachsel-Moncho, Gro Vatne Røsland, Muntequa Ishtiaq Siraji, Monica Hellesøy, Austin J. Rayford et al. · 2020 · Journal of Thoracic Oncology
40. Neurofibromin and suppression of tumorigenesis: beyond the GAP
    Juan Mo, Stefanie L. Moye, Renee M. McKay, L. Le · 2022 · Oncogene
41. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
    Filip Jankú, Philipp Angenendt, Apostolia Maria Tsimberidou, Siqing Fu, Aung Naing, Gerald Steven Falchook, David S. Hong, Veronica R. Holley, Goran Cabrilo, Jennifer J. Wheler et al. · 2015 · Oncotarget
42. MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
    Yan Feng, Praveena Shree Thiagarajan, Patrick C. Ma · 2012 · Journal of Thoracic Oncology
43. Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
    Charlotte K.Y. Ng, Anne Maria Schultheis, François‐Clément Bidard, Britta Weigelt, Jorge Sergio Reis-Filho · 2015 · JNCI Journal of the National Cancer Institute
44. Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
    Xueda Hu, Zemin Zhang · 2015 · Trends in Genetics
45. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Natalie Andrews Wright, Glenwood D. Goss · 2019 · Translational Lung Cancer Research
46. The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
    Matteo Canale, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Paola Ulivi · 2022 · Cancers
47. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer
    Jiaye Lu, Jingwei Li, Ziyou Lin, Huaxuan Li, Linlin Lou, Wen Ding, Shumin Ouyang, Yonghui Wu, Yuanzhen Wen, Xiaobing Chen et al. · 2023 · Cancer Letters
48. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells
    Haiying Cheng, Zhenfeng Zhang, Ruth Rodriguez Barrueco, Alain Borczuk, Huijie Liu, Jiyang Yu, José M. Silva, Simon K. Cheng, Roman Perez-Soler, Balázs Halmos · 2015 · Oncotarget
49. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
    Arena, Sabrina, Siravegna, Giulia, Mussolin, Benedetta, Kearns, Jeffrey D., Wolf, Beni B., Misale, Sandra, Lazzari, Luca, Bertotti, Andrea, Trusolino, Livio, Adjei, Alex A. et al. · 2016 · Science Translational Medicine
50. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies
    Meghan J. Campo, David E. Gerber, Justin F. Gainor, Rebecca Suk Heist, Jennifer S. Temel, Alice Tsang Shaw, Panos Fidias, Alona Muzikansky, Jeffrey A. Engelman, Lecia Van Dam Sequist · 2016 · Journal of Thoracic Oncology
51. Capmatinib for the treatment of non-small cell lung cancer
    Johan Vansteenkiste, Charlotte Van de Kerkhove, Els Wauters, Pierre Van Mol · 2019 · Expert Review of Anticancer Therapy
52. Clinical Evolution of Epithelial–Mesenchymal Transition in Human Carcinomas
    Tony A. Navas, Robert J. Kinders, Scott M. Lawrence, Katherine V. Ferry‐Galow, Suzanne D. Borgel, Melinda G. Hollingshead, Apurva K. Srivastava, Sergio Y. Alcoser, Hala R. Makhlouf, Rodrigo F. Chuaqui et al. · 2019 · Cancer Research
53. Cellular rewiring in lethal prostate cancer: the architect of drug resistance
    Marc Carceles‐Cordon, William Kevin Kelly, Leonard G. Gomella, Karen E. Knudsen, Verónica Rodríguez-Bravo, Josep M. Domingo Domenech · 2020 · Nature Reviews Urology
54. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations
    Philippe Jamme, Marie Fernandes, Marie‐Christine Copin, Clotilde Descarpentries, Fabienne Escande, Angela Morabito, Valérie Grégoire, Matthieu Jamme, Simon Baldacci, David Tulasne et al. · 2020 · Journal of Thoracic Oncology
55. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
    Xuejin Ou, Ge Gao, Inbar A Habaz, Yongsheng Wang · 2024 · MedComm
56. β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
    Sohei Nakayama, Natasha Sng, Julián Carretero, Robert S. Welner, Yuichiro Hayashi, Mihoko Yamamoto, Alistair J. Tan, Norihiro Yamaguchi, Hiroyuki Yasuda, Danan Li et al. · 2014 · Cancer Research
57. Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma
    E-Ryung Choi, Ho Yun Lee, Ji Yun Jeong, Yoon‐La Choi, Jhingook Kim, Jungmin Bae, Kyung Soo Lee, Young Mog Shim · 2016 · Oncotarget
58. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
    Kimio Yonesaka, Kenji Hirotani, Hisato Kawakami, Masayuki Takeda, Hiroyasu Kaneda, Kazuko Sakai, Isamu Okamoto, Kazuto Nishio, Pasi Antero Janne, Kazuhiko Nakagawa · 2015 · Oncogene
59. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
    Gregory J. Riely, Helena Alexandra Yu · 2015 · Clinical Cancer Research
60. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma
    Satoshi Watanabe, Takashi Sone, Tomoharu Matsui, Kenta Yamamura, Mayuko Tani, Akihito Okazaki, Koji Kurokawa, Yuichi Tambo, Hazuki Takato, Noriyuki Ohkura et al. · 2013 · Lung Cancer
61. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vázquez‐Martín, Sílvia Cufí, Cristina Oliveras‐Ferraros, Violeta Zenobia Torres-Garcia, Bruna Corominas-Faja, Elisabet Cuyàs, Rosa Bonavia, Joana Visa, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán et al. · 2013 · Scientific Reports
62. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
    Colin R. Lindsay, Vincent Faugeroux, Stefan Michiels, Emma Pailler, Francesco Facchinetti, Dan Ou, Maria Virginia Bluthgen, Chloé Pannet, Maud Ngo‐Camus, Guillaume Bescher et al. · 2017 · Annals of Oncology
63. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers
    Chen Chen, Wei-Ran Liu, Bin Zhang, Lian-Min Zhang, Chenguang Li, Chang Liu, Hua Zhang, Yansong Huo, Yu-Chen Ma, Pengfei Tian et al. · 2020 · Cancer Letters
64. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
    Xiangyu Sun, Ping Zhao, Jierou Lin, Kun Chen, Jianliang Shen · 2023 · Cancer Drug Resistance
65. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
    Patrick Yung Wen, Antonio M. P. Omuro, Manmeet Singh Ahluwalia, Hassan M. Fathallah‐Shaykh, Nimish A. Mohile, Joanne J. Lager, Alexander Laird, Jiali Tang, Jason Jiang, Coumaran Égile et al. · 2015 · Neuro-Oncology
66. Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC
    Chen, Kai, Zhou, Fei, Shen, Wenxiang, Jiang, Tao, Wu, Xue, Tong, Xiaoling, Shao, Yang W., Qin, Songbing, Zhou, Caicun · 2017 · Journal of Thoracic Oncology
67. Cell signaling and cancer: a mechanistic insight into drug resistance
    Panda, Munmun, Biswal, Bijesh K. · 2019 · Molecular Biology Reports
68. Prognostic and predictive biomarkers in lung cancer. A review
    Erik Thunnissen, Kimberly Van der Oord, Michael den Bakker · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
69. Translational research in oncology—10 years of progress and future prospects
    James H. Doroshow, Shivaani Kummar · 2014 · Nature Reviews Clinical Oncology
70. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma
    Huibin Song, Dongcheng Liu, Lingwei Wang, Kaisheng Liu, Chen Chen, Le Wang, Yi Ren, Bing Ju, Fuhua Zhong, Xingyu Jiang et al. · 2022 · Molecular Cancer
71. Mechanisms of acquired resistance to tyrosine kinase inhibitors
    Yifan Chen, Liwu Fu · 2011 · Acta Pharmaceutica Sinica B
72. Na/K Pump and Beyond: Na/K-ATPase as a Modulator of Apoptosis and Autophagy
    Cassiano Felippe Gonçalves-de-Albuquerque, Adriana Ribeiro Silva, Camila Ignácio da Silva, Hugo Caire Castro-Faria-Neto, Patrícia Burth · 2017 · Molecules
73. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
    Zachary Alan Yochum, Jessica Cades, Lucia Mazzacurati, Neil M. Neumann, Susheel K. Khetarpal, Suman Chatterjee, Hailun Wang, Myriam A. Attar, Eric H.‐B. Huang, Sarah N.H. Chatley et al. · 2017 · Molecular Cancer Research
74. Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells
    Karim Aljakouch, Tatjana Lechtonen, Hesham K. Yosef, Mohamad K. Hammoud, Wissam Alsaidi, Carsten Kötting, Carolin Mügge, Robert Kourist, Samir F. El‐Mashtoly, Klaus Bernhard Gerwert · 2018 · Angewandte Chemie International Edition
75. Drug Resistance to EGFR Inhibitors in Lung Cancer
    Osamu Tetsu, Matthew J. Hangauer, Janyaporn Phuchareon, David W. Eisele, Frank P. McCormick · 2016 · Chemotherapy
76. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
    Katharine D. Grugan, Keri Dorn, Stephen W. Jarantow, Barbara S. Bushey, José R. Pardinas, Sylvie G. Laquerre, Sheri L. Moores, Mark L. Chiu · 2016 · mAbs
77. Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
    John R. Goffin, Kevin M. Zbuk · 2013 · Clinical Therapeutics
78. Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
    Laura E. MacConaill, Elizabeth Garcia, Priyanka Shivdasani, Matthew D. Ducar, Ravali Adusumilli, Marc Breneiser, Mark N. Byrne, Lawrence P. Chung, Jodie Conneely, Lauren Crosby et al. · 2014 · Journal of Molecular Diagnostics
79. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
    Noemı́ Reguart, Rafael Rosell, Felipe Cardenal, Andrés Felipe Cardona, Dolores Isla, Ramón Palmero, Teresa Morán, Christian Diego Rolfo, Maria Cinta Pallarès, Amelia Insa et al. · 2014 · Lung Cancer
80. Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
    Caicun Zhou, Luan Di Yao · 2015 · Journal of Thoracic Oncology
81. Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
    Takahisa Kawamura, Hirotsugu Kenmotsu, Tetsuhiko Taira, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita P. Mori et al. · 2016 · Cancer Science
82. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
    Kenichi Suda, Isao Murakami, Kazuko Sakai, Hiroshi Mizuuchi, Shigeki Shimizu, Katsuaki Sato, Kenji Tomizawa, Shuta Tomida, Yasushi Yatabe, Kazuto Nishio et al. · 2015 · Scientific Reports
83. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
    Viktoria von Manstein, Chul Yang, Diane E. Richter, Natalia Delis, Vida Vafaizadeh, Bernd Groner · 2014 · Current Signal Transduction Therapy
84. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer
    Oscar G. Arrieta, Andrés Felipe Cardona, Luis Corrales, Alma Delia Campos-Parra, Roberto Sánchez-Reyes, Eduardo Amieva-Rivera, July Katherine Rodríguez, Carlos Alberto Vargas, Hernán Carranza, Jorge Miguel Otero et al. · 2014 · Lung Cancer
85. Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology
    Jeonghun Han, Yukyung Jun, Kim Ys, Hong-Hoa Hoang, Yeonjoo Jung, Suyeon Kim, Jaesang Kim, Robert H. Austin, Sanghyuk Lee, Sungsu Park · 2016 · Proceedings of the National Academy of Sciences
86. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    William Kelly, Neil J. Shah, Deepa Suresh Subramaniam · 2018 · Frontiers in Oncology
87. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
    Ya-Fei Du, Feride Karatekin, Wendy Kehan Wang, Wanjin Hong, T. K. B. Gandhi · 2025 · Pharmacological Reviews
88. The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis
    Simon Ekman, Murry W. Wynes, Fred R. Hirsch · 2012 · Journal of Thoracic Oncology
89. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis
    Zan-Feng Wang, Shengxiang Ren, Wěi Li, Guanghui Gao · 2018 · BMC Cancer
90. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells
    Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto et al. · 2018 · Molecular Cancer Research
91. Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study
    Hochmair, Maximilian J, Morabito, Alessandro, Hao, Desiree, Yang, Cheng-Ta, Soo, Ross A, Yang, James C-H, Gucalp, Rasim, Halmos, Balazs, Wang, Lara, Märten, Angela et al. · 2019 · Future Oncology
92. PD ‐L1 testing for lung cancer in the UK : recognizing the challenges for implementation
    Ian A. Cree, Richard Booton, Paul Cane, John R. Gosney, Merdol Ibrahim, Keith M. Kerr, Rohit Lal, Conrad R. Lewanski, Neal Navani, Andrew Gordon Nicholson et al. · 2016 · Histopathology
93. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis
    Elisa Roca, Cristina Gurizzan, Vito Amoroso, William Vermi, Vittorio Domenico Ferrari, Alfredo Berruti · 2017 · Cancer Treatment Reviews
94. Quantifying Selection with Pool-Seq Time Series Data
    Thomas Taus, Andreas Futschik, Christian Schlötterer · 2017 · Molecular Biology and Evolution
95. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
    Yi Le, Yiyuan Gan, Yihong Fu, Jiamin Liu, Wen Li, Xue Zou, Zhixu Zhou, Zhenchao Wang, Guiping Ouyang, Longjia Yan · 2020 · Journal of Enzyme Inhibition and Medicinal Chemistry
96. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
    Ravi S. Narayan, Piet Molenaar, Jian Teng, Fleur M.G. Cornelissen, Irene Roelofs, Renée X. de Menezes, Rogier Dik, Tonny Lagerweij, Yoran Broersma, Naomi Petersen et al. · 2020 · Nature Communications
97. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
    Guohua Li, Qiang Qu, Ting-Ting Qi, Xin-Qi Teng, Haihong Zhu, Jiaojiao Wang, Qiong Lu, Jian Qu · 2021 · Journal of Experimental & Clinical Cancer Research
98. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
    Rodrigo Romero, Tinyi Chu, Tania J González-Robles, Perianne Smith, Yubin Xie, Harmanpreet Kaur, Sara Yoder, Huiyong Zhao, Chenyi Mao, Wenfei Kang et al. · 2024 · Nature Cancer
99. HSP90 as a platform for the assembly of more effective cancer chemotherapy
    Luke J. Whitesell, NU Lin · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
100. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
     Jun Soo Ham, Seokhwi Kim, Hee Kyung Kim, Seonggyu Byeon, Jong‐Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon‐La Choi, Joungho Han et al. · 2016 · Journal of Thoracic Oncology